Although MTHFD2L expression levels in AML are higher than normal tissues when compared to MTHFD2 levels, MTHFD2 seems a more attractive therapeutic target due to the fact that MTHFD2L is unable to compensate the loss of MTHFD2. The gene discussed is MTHFD2; the disease is acute myeloid leukemia.